Handelsavisen
prelaunch
Companies ›Healthcare ›CRSP
CR
CRSP — Nasdaq Biotechnology & Life-Science Tools

CRISPR Therapeutics AG

$49,92
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
4,8B USD
P/E
—
EV / Rev
771,4x
Div yield
—
Op margin
-18 933,6 %
ROE
-32,0 %
Net margin
-16 569,8 %
Debt / equity
—
Beta
—
52w range
—
Volume
10,7k
Day range
$51,11–$54,52
Prev close
$51,59
Open
$51,71
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

CRISPR Therapeutics AG is classified under Healthcare / Pharmaceuticals and appears not currently profitable on the latest normalized snapshot.

Business. CRISPR Therapeutics AG is classified under Healthcare / Pharmaceuticals and appears not currently profitable on the latest normalized snapshot.

Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
Generated · rules-based
Sell-side consensus
BUY24 analysts
13 buy11 hold0 sell
Avg 12m price target82,53

Analyst recommendations

24 analysts · consensus Buy
Buy13
Hold11
Sell0
12-month price target
82,53
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
24 analysts · indicative
Ownership→
T. Rowe Price Investment Management, Inc.
largest disclosed fund holder
Profitability→
-32,0 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning CRSP.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to CRSP. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    CRISPR Therapeutics AG is classified under Healthcare / Pharmaceuticals and appears not currently profitable on the latest normalized snapshot.

    Classification99 %
    SectorHealth Care
    Industry groupBiotechnology & Life-Science Tools
    AI synthesis
    GENERATED

    CRISPR Therapeutics AG (CRSP) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.93 (rule-based classification). Capital structure on the latest snapshot: total assets 2,725,820,000 USD, total equity 1,814,556,000, short-term debt 0, long-term debt 0. Net cash position is approximately 2,441,785,000 USD. Self-calculated market cap is 5,149,306,333 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 1,458,000, gross profit 0, operating income -130,248,000, net income -122,931,000. Return on equity ~-32.0%. Return on assets ~-21.3%. Operating-cash-flow to net-income ratio is 0.59. Risk profile from automated assessment: liquidity risk low, dilution risk medium. Flags: Source documents mention dilution or offering risk.. Recent news context: [TRIGGER] allocator_boost: allocator_boost (allocator) on CRSP — watcher=allocator; producer_version=ws49-p2a-v2; plan_date=2026-08-01; rank=11; ev=8.215653; company_id=2fbae7a4-166d-47f8-bb46-da8e9ff730cc; term_contributions={'event_proximity': 2.01096, 'gradability': 2.0, 'staleness': 4.204693, 'credibility_interest': 0.0}; days_since_analysis=66; pending_promises=0; reason=Allocator coverage boost rank #11 EV=8.215653 for CRSP (hot+stale; days_since=66); calendar_week={'next_event_date': '2026-08-03', 'days_until': 2, 'bases': ['expected (estimated date)'], 'in_plan_rows': True, 'never_analyzed': False}; contributing_watchers=allocator (source=allocator; url=allocator:2026-08-01:CRSP). Additional context: allocator_boost: watcher=allocator; producer_version=ws49-p2a-v2; plan_date=2026-08-01; rank=11; ev=8.215653; company_id=2fbae7a4-166d-47f8-bb46-da8e9ff730cc; term_contributions={'event_proximity': 2.01096, 'gradability': 2.0, 'staleness': 4.204693, 'credibility_interest': 0.0}; days_since_analysis=66; pending_promises=0; reason=Allocator coverage boost rank #11 EV=8.215653 for CRSP (hot+stale; days_since=66); calendar_week={'next_event_date': '2026-08-03', 'days_until': 2, 'bases': ['expected (estimated date)'], 'in_plan_rows': True, 'never_analyzed': False}; contributing_watchers=allocator.

    Key takeaways
    • Return on equity is about -32.0%.
    • Debt to equity is about 0.0x.
    • [TRIGGER] allocator_boost: allocator_boost (allocator) on CRSP — watcher=allocator; producer_version=ws49-p2a-v2; plan_date=2026-08-01; rank=11; ev=8.215653; company_id=2fbae7a4-166d-47f8-bb46-da8e9ff730cc; term_contributions={'event_proximity': 2.01096, 'gradability': 2.0, 'staleness': 4.204693, 'credibility_interest': 0.0}; days_since_analysis=66; pending_promises=0; reason=Allocator coverage boost rank #11 EV=8.215653 for CRSP (hot+stale; days_since=66); calendar_week={'next_event_date': '2026-08-03', 'days_until': 2, 'bases': ['expected (estimated date)'], 'in_plan_rows': True, 'never_analyzed': False}; contributing_watchers=allocator (source=allocator; url=allocator:2026-08-01:CRSP)
    • Companyfacts coverage was partial; recent filing facts backfilled accounts_receivable, intangible_assets.
    • 10-Q --12-31 0001674416 Q1 false 00-0000000 http://fasb.org/srt/2025#ChiefExecutiveOfficerMember 0001674416 crsp:TwoThousandTwentyOneAtMarketOfferingMember crsp:SalesAgreementWithJefferiesLLCMember srt:MaximumMember 2021-01-01 2021-01-31 0001674416 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001674416 2022-01-01 2022-12-31 0001674416 crsp:VertexPharmaceuticalsIncMember 2026-01-01 2026-03-31 0001674416 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001674416 crsp:ConvertibleSeniorNotesDueTwoThousandThirtyoneMember 2025-12-31 0001674416 crsp:MarketableEquitySecuritiesMember 2025-12-31 0001674416 crsp:LaboratoryEquipmentMember 2026-03-31 0001674416 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001674416 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001674416 crsp:MarketableDebtSecuritiesMember 2025-01-01 2025-03-31 0001674416 us-gaap:ConstructionInProgressMember 2026-03-31 0001674416 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember crsp:CertificatesAndTermDepositsMember 2026-03-31 0001674416 2023-06-08 0001674416 us-gaap:EmployeeStockMember 2026-01-01 2026-03-31 0001674416 crsp:MarketableDebtSecuritiesMember 2026-03-31 0001674416 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001674416 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001674416 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001674416 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001674416 crsp:CorporateEquitySecuritiesMember 2025-12-31 0001674416 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001674416 us-gaap:CommercialPaperMember 2026-03-31 0001674416 us-gaap:RetainedEarningsMember 2025-03-31 0001674416 crsp:SiriusTherapeuticsMember 2025-05-19 0001674416 crsp:MarketableEquitySecuritiesMember 2026-01-01 2026-03-31 0001674416 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001674416 crsp:CapitalBandMember 2026-03-31 0001674416 us-gaap:RetainedEarningsMember 2025-12-31 0001674416 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001674416 crsp:FurnitureFixturesAndOtherMember 2025-12-31 0001674416 us-gaap:TreasuryStockCommonMember 2024-12-31 0001674416 us-gaap:MoneyMarketFundsMember 2025-12-31 0001674416 us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-03-31 0001674416 2026-03-16 2026-03-16 0001674416 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001674416 crsp:VertexPharmaceuticalsIncMember us-gaap:CollaborativeArrangementMember 2026-03-31 0001674416 us-gaap:LeaseholdImprovementsMember 2026-03-31 0001674416 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001674416 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2026-03-31 0001674416 crsp:TwoThousandTwentyOneAtMarketOfferingMember crsp:SalesAgreementWithJefferiesLLCMember 2025-01-01 2025-03-31 0001674416 crsp:AmendedAndRestatedVertexJointDevelopmentAndCommercializationAgreementMember crsp:VertexPharmaceuticalsIncorporatedAndItsCertainSubsidiariesMember 2023-01-01 2023-12-31 0001674416 us-gaap:LetterOfCreditMember 2025-12-31 0001674416 2025-12-31 0001674416 crsp:MarketableDebtSecuritiesMember 2025-12-31 0001674416 us-gaap:OperatingSegmentsMember crsp:VertexHemoglobinopathyAgreementsMember 2025-01-01 2025-03-31 0001674416 us-gaap:CommercialPaperMember 2025-12-31 0001674416 crsp:NonExLicenseAgreementMember crsp:VertexPharmaceuticalsIncorporatedAndItsCertainSubsidiariesMember 2026-03-31 0001674416 2026-03-31 0001674416 crsp:TwoThousandTwentyOneAtMarketOfferingMember 2025-12-31 0001674416 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001674416 2025-01-01 2025-03-31 0001674416 us-gaap:IntellectualPropertyMember 2025-10-01 2025-12-31 0001674416 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2025-12-31 0001674416 crsp:TwoThousandTwentyFiveAtMarketOfferingMember crsp:SalesAgreementWithJefferiesLLCMember srt:MaximumMember 2025-10-01 2025-10-31 0001674416 2024-12-31 0001674416 2026-04-30 0001674416 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001674416 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001674416 us-gaap:CorporateDebtSecuritiesMember 2025-12-31 0001674416 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001674416 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001674416 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001674416 us-gaap:RestrictedStockMember 2025-12-31 0001674416 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001674416 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001674416 crsp:AmendedAndRestatedVertexJointDevelopmentAndCommercializationAgreementMember 2021-12-31 0001674416 crsp:ConvertibleSeniorNotesDueTwoThousandThirtyoneMember 2026-03-16 2026-03-16 0001674416 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0001674416 crsp:MarketableDebtSecuritiesMember 2026-01-01 2026-03-31 0001674416 us-gaap:OperatingSegmentsMember us-gaap:GrantMember 2025-01-01 2025-03-31 0001674416 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001674416 us-gaap:TreasuryStockCommonMember 2025-03-31 0001674416 us-gaap:CommonStockMember 2026-03-31 0001674416 srt:MaximumMember 2023-06-08 0001674416 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2025-12-31 0001674416 us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001674416 us-gaap:TreasuryStockCommonMember 2026-03-31 0001674416 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001674416 crsp:CollaborationRevenueMember us-gaap:OperatingSegmentsMember 2026-01-01 2026-03-31 0001674416 crsp:VertexPharmaceuticalsIncMember 2025-01-01 2025-03-31 0001674416 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001674416 2024-01-01 2024-12-31 0001674416 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001674416 crsp:TwoThousandTwentyFiveAtMarketOfferingMember crsp:SalesAgreementWithJefferiesLLCMember 2026-03-31 0001674416 us-gaap:ConstructionInProgressMember 2025-12-31 0001674416 us-gaap:EmployeeStockOptionMember 2026-03-31 0001674416 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001674416 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001674416 us-gaap:CorporateDebtSecuritiesMember 2026-03-31 0001674416 us-gaap:ResearchAndDevelopmentExpenseMember 2026-01-01 2026-03-31 0001674416 us-gaap:CollaborativeArrangementMember crsp:VertexPharmaceuticalsIncorporatedAndItsCertainSubsidiariesMember 2026-01-01 2026-03-31 0001674416 us-gaap:EmployeeStockMember 2025-01-01 2025-03-31 0001674416 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2026-03-31 0001674416 crsp:UnvestedRestrictedCommonSharesMember 2026-01-01 2026-03-31 0001674416 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2026-03-31 0001674416 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-03-31 0001674416 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001674416 srt:MaximumMember crsp:SiriusTherapeuticsMember 2025-05-19 2025-05-19 0001674416 us-gaap:FairValueInputsLevel1Member us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001674416 crsp:MarketableEquitySecuritiesMember 2025-01-01 2025-03-31 0001674416 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001674416 crsp:CollaborationRevenueMember 2025-01-01 2025-03-31 0001674416 crsp:SiriusTherapeuticsMember 2025-05-19 2025-05-19 0001674416 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001674416 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001674416 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001674416 crsp:SiriusTherapeuticsMember 2026-01-01 2026-03-31 0001674416 2025-03-31 0001674416 crsp:MarketableEquitySecuritiesMember 2026-03-31 0001674416 us-gaap:OperatingSegmentsMember 2025-01-01 2025-03-31 0001674416 crsp:CollaborationRevenueMember 2026-01-01 2026-03-31 0001674416 crsp:AssumedConversionOfNotesMember 2026-01-01 2026-03-31 0001674416 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2026-03-31 0001674416 2023-01-01 2023-12-31 0001674416 crsp:ConvertibleSeniorNotesDueTwoThousandThirtyoneMember 2026-03-16 0001674416 crsp:VertexPharmaceuticalsIncMember 2024-05-01 2024-05-31 0001674416 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001674416 us-gaap:RetainedEarningsMember 2026-03-31 0001674416 us-gaap:RestrictedStockMember 2026-03-31 0001674416 us-gaap:CommonStockMember 2025-12-31 0001674416 us-gaap:OperatingSegmentsMember 2026-01-01 2026-03-31 0001674416 crsp:CorporateEquitySecuritiesMember 2026-03-31 0001674416 us-gaap:MoneyMarketFundsMember 2026-03-31 0001674416 us-gaap:OperatingSegmentsMember crsp:SiriusAgreementMember 2025-01-01 2025-03-31 0001674416 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001674416 crsp:VertexPharmaceuticalsIncMember 2026-03-31 0001674416 us-gaap:GeneralAndAdministrativeExpenseMember 2026-01-01 2026-03-31 0001674416 crsp:TwoThousandTwentyFiveAtMarketOfferingMember crsp:SalesAgreementWithJefferiesLLCMember 2026-01-01 2026-03-31 0001674416 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001674416 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001674416 crsp:FurnitureFixturesAndOtherMember 2026-03-31 0001674416 us-gaap:GrantMember 2025-01-01 2025-03-31 0001674416 crsp:LaboratoryEquipmentMember 2025-12-31 0001674416 us-gaap:FairValueMeasurementsRecurringMember crsp:CertificatesAndTermDepositsMember 2026-03-31 0001674416 us-gaap:ComputerEquipmentMember 2026-03-31 0001674416 crsp:TwoThousandTwentyOneAtMarketOfferingMember 2025-01-01 2025-12-31 0001674416 us-gaap:CommonStockMember 2025-03-31 0001674416 crsp:SiriusTherapeuticsMember 2026-03-31 0001674416 crsp:AssumedConversionOfNotesMember 2025-01-01 2025-03-31 0001674416 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001674416 crsp:AmendedAndRestatedVertexJointDevelopmentAndCommercializationAgreementMember crsp:VertexPharmaceuticalsIncorporatedAndItsCertainSubsidiariesMember 2021-12-31 0001674416 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001674416 us-gaap:RetainedEarningsMember 2024-12-31 0001674416 crsp:ConvertibleSeniorNotesDueTwoThousandThirtyoneMember 2026-01-01 2026-03-31 0001674416 us-gaap:TreasuryStockCommonMember 2025-12-31 0001674416 us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001674416 us-gaap:OperatingSegmentsMember us-gaap:GrantMember 2026-01-01 2026-03-31 0001674416 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001674416 crsp:ConvertibleSeniorNotesDueTwoThousandThirtyoneMember 2026-03-31 0001674416 us-gaap:OperatingSegmentsMember crsp:SiriusAgreementMember 2026-01-01 2026-03-31 0001674416 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001674416 crsp:CollaborationRevenueMember us-gaap:OperatingSegmentsMember 2025-01-01 2025-03-31 0001674416 srt:MaximumMember crsp:ConvertibleSeniorNotesDueTwoThousandThirtyoneMember 2026-03-31 0001674416 us-gaap:FairValueInputsLevel1Member us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001674416 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2025-12-31 0001674416 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001674416 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001674416 us-gaap:ComputerEquipmentMember 2025-12-31 0001674416 crsp:VertexPharmaceuticalsIncorporatedAndItsCertainSubsidiariesMember 2025-01-01 2025-03-31 0001674416 us-gaap:LeaseholdImprovementsMember 2025-12-31 0001674416 crsp:CollaborativeArrangementMaterialRightsMember crsp:VertexPharmaceuticalsIncorporatedAndItsCertainSubsidiariesMember 2026-03-31 0001674416 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001674416 us-gaap:OperatingSegmentsMember crsp:VertexHemoglobinopathyAgreementsMember 2026-01-01 2026-03-31 0001674416 us-gaap:GrantMember 2026-01-01 2026-03-31 0001674416 crsp:TwoThousandAndFifteenCollaborationAgreementMember crsp:VertexPharmaceuticalsIncorporatedAndItsCertainSubsidiariesMember 2026-03-31 0001674416 2026-01-01 2026-03-31 0001674416 crsp:VertexPharmaceuticalsIncorporatedAndItsCertainSubsidiariesMember 2026-01-01 2026-03-31 0001674416 us-gaap:LetterOfCreditMember 2026-03-31 0001674416 crsp:UnvestedRestrictedCommonSharesMember 2025-01-01 2025-03-31 0001674416 us-gaap:RestrictedStockMember 2026-01-01 2026-03-31 0001674416 srt:MaximumMember crsp:SiriusTherapeuticsMember 2026-01-01 2026-03-31 0001674416 us-gaap:CertificatesOfDepositMember 2025-12-31 0001674416 us-gaap:CertificatesOfDepositMember 2026-03-31 0001674416 us-gaap:CommonStockMember 2024-12-31 0001674416 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001674416 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2025-12-31 xbrli:pure xbrli:shares iso4217:CHF xbrli:shares iso4217:CHF utr:D iso4217:USD xbrli:shares crsp:Segment iso4217:USD Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-31
    Q4 2025 · Quarter highlights

    Revenue $1.5M; Operating income -$130.2M.

    Revenue$1.5M
    Operating income-$130.2M
    Net income-$122.9M
    Free cash flow-$109.4M
    EPS—
    Operating cash flow-$108.9M
    Financials
    Income statement
    Revenue$1.5M
    Gross profit—
    Operating income-$130.2M
    Net income-$122.9M
    Margins
    Gross margin—
    Operating margin-8933.3%
    Net margin-8431.5%
    FCF margin-7503.5%
    Balance sheet
    Total assets$2.73B
    Total liabilities$911.3M
    Total equity$1.81B
    Cash & equivalents$423.3M
    Long-term debt—
    Cash flow
    Operating cash flow-$108.9M
    CapEx$504.0k
    Free cash flow-$109.4M
    SBC$16.3M
    P&L flow · revenue → net income
    Revenue $1.5MOperating costs $131.7MNet income $122.9M
    Highlights
    • ▍Revenue $1.5M
    • ▍Operating income -$130.2M
    • ▍Net margin -8431.5%

    Valuation FY

    Market price
    $49,92
    Market cap
    $5.15B
    Enterprise valueⓘ
    $2.71B
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    771.4x
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    2.8x
    P / Tangible bookⓘ
    2.8x
    Tangible book
    $1.81B
    Net cashⓘ
    $2.44B
    Current ratioⓘ
    18.0
    Debt / equityⓘ
    —
    ROAⓘ
    -21.3%
    ROEⓘ
    -32.0%
    Cash conversionⓘ
    59.0%
    CapEx / revenueⓘ
    26.0%
    SBC / revenueⓘ
    20.7%
    Dilution ratioⓘ
    -0.4%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryBiotechnology & Life-Science Tools27,7B node revenueIQV 58,8%CRL 14,5%MEDP 9,1%ALKS 5,3%PIII 5,3%ORGO 2,0%NAGE 0,5%SPRY 0,3%Other 4,2%
    Source: company disclosures · own-taxonomy revenue-covered setCRSP 0,0% · rank #46 of 78

    Business relationships

    Business relationships6 disclosed relationships · 2 types · extracted from filings & disclosures
    Subsidiaries4
    EX21:003bb592cf42EX21:003bb592cf42Subsidiarie97%
    EX21:1d4b5f6dd0eaEX21:1d4b5f6dd0eaSubsidiarie97%
    EX21:a7f067d6a343EX21:a7f067d6a343Subsidiarie97%
    EX21:b7bcf4250504EX21:b7bcf4250504Subsidiarie97%

    Supply chain

    Vendors → CRSP ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSCRSPCRSPCRISPR Therapeutics AG6 entitiesELI LILLY AND COMPANYPharmaceuticalsUSVERTEX PHARMACEUTICALSPharmaceuticalsUS
    2 mentions in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    Peer comparison8 peers · vs CRSP · multiples and returns
    IQ
    IQV—
    Iqvia Holdings Inc
    $181,94
    30,9B USD
    P/E
    22,7x
    — vs self
    Div yield
    —
    — vs self
    ROE
    21,9 %
    +53,9 vs self
    CR
    CRL—
    Charles River Laboratories
    $230,87
    11,4B USD
    P/E
    —
    — vs self
    Div yield
    —
    — vs self
    ROE
    -4,6 %
    +27,5 vs self
    ME
    MEDP—
    Medpace Holdings Inc
    $576,00
    16,7B USD
    P/E
    34,4x
    — vs self
    Div yield
    —
    — vs self
    ROE
    75,4 %
    +107,5 vs self
    AL
    ALKS—
    Alkermes PLC
    $49,53
    8,2B USD
    P/E
    39,8x
    — vs self
    Div yield
    —
    — vs self
    ROE
    8,4 %
    +40,4 vs self
    PI
    PIII—
    P3 Health Partners Inc
    $10,20
    73,8M USD
    P/E
    —
    — vs self
    Div yield
    —
    — vs self
    ROE
    95,3 %
    +127,4 vs self
    OR
    ORGO—
    Organogenesis Holdings Inc
    $2,38
    306,2M USD
    P/E
    9,0x
    — vs self
    Div yield
    —
    — vs self
    ROE
    8,5 %
    +40,6 vs self
    NA
    NAGE—
    Niagen Bioscience Inc
    $3,53
    281,1M USD
    P/E
    17,4x
    — vs self
    Div yield
    —
    — vs self
    ROE
    22,7 %
    +54,8 vs self
    SP
    SPRY—
    Ars Pharmaceuticals Inc
    $5,51
    547,1M USD
    P/E
    —
    — vs self
    Div yield
    —
    — vs self
    ROE
    -149,9 %
    -117,9 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 44 %
    EPS
    Consensus EPS
    -4,94
    Predicted surprise
    -0,05
    Beat probability
    44 %
    Analysts
    24
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    revision ratio -0,01 · as of 2026-08-01 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate-4,94
    Revenue—no estimate—no estimate28,6M USD
    Operating income—no estimate—no estimate-525,9M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Corporate eventM&A horizon
    M&A probabilityconf 3 %
    Probability
    3 %
    Base rate
    3 %
    Band
    —
    180-day horizon · target 2027-01-20 · 1,0× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution24 analysts
    Strong buy4
    Buy9
    Hold11
    Sell0
    Strong sell0
    12-month price target$82,53 · Median $76,00
    Low $44,00High $291,00
    Operating income · consensus-525,9M USD
    EPS surprise
    −9,3 %
    reported vs consensus · miss
    Revenue surprise
    −87,7 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$44,00
    Mean$82,53
    Median$76,00
    High$291,00
    Spot$49,92
    +65.3 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskMedium
    Liquidity riskLow
    Filing-based flags
    • Source documents mention dilution or offering risk.

    Benchmarks vs cohort

    Op Margin-18 933,7 %Bottom quartile
    Net Margin-16 569,8 %Bottom quartile
    ROE-32,0 %Below median
    Capex / Rev26,0 %Best in class
    D/E0,00Above median
    Cash Conv0,59Below median

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    3 %
    Base rate
    3 %
    Band
    Low
    180-day horizon · target 2027-01-20 · 1,0× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 449 934 sh12 exercises · 21 grants14 insiders
    • Rommel ChristianDirector · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
    • George SimeonDirector · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
    • Behbahani AliDirector · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
    • Fardis MariaDirector · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
    • Fleming Harold EdwardDirector · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
    • Greene JohnDirector · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
    • High Katherine ADirector · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
    • Mahatme SandeshDirector · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
    • Morrison BriggsDirector · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
    • Treco Douglas ADirector · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
    • Prasad RajuChief Financial Officer · Restricted Stock Units → Common SharesAcquired 19 500grant · 2026-05-29
    • KASINGER JAMES R.General Counsel and Secretary · Restricted Stock Units → Common SharesAcquired 17 000grant · 2026-05-29
    • Patel NaimishChief Medical Officer · Restricted Stock Units → Common SharesAcquired 22 000grant · 2026-05-29
    • Patel NaimishChief Medical Officer · Restricted Stock Units → Common SharesDisposed 10 000exercise · 2026-05-28
    • KASINGER JAMES R.General Counsel and Secretary · Restricted Stock Units → Common SharesAcquired 25 000grant · 2026-03-20
    • KASINGER JAMES R.General Counsel and Secretary · Stock Option (Right to Buy) → Common SharesAcquired 38 499 @ $46,24grant · 2026-03-20
    • KASINGER JAMES R.General Counsel and Secretary · Restricted Stock Units → Common SharesDisposed 6 250exercise · 2026-03-20
    • Patel NaimishChief Medical Officer · Restricted Stock Units → Common SharesAcquired 30 000grant · 2026-03-20
    • Patel NaimishChief Medical Officer · Stock Option (Right to Buy) → Common SharesAcquired 38 499 @ $46,24grant · 2026-03-20
    • Prasad RajuChief Financial Officer · Restricted Stock Units → Common SharesDisposed 6 250exercise · 2026-03-20
    • Prasad RajuChief Financial Officer · Restricted Stock Units → Common SharesAcquired 27 500grant · 2026-03-20
    • Prasad RajuChief Financial Officer · Stock Option (Right to Buy) → Common SharesAcquired 38 499 @ $46,24grant · 2026-03-20
    • Kulkarni SamarthDirector, Chief Executive Officer · Restricted Stock Units → Common SharesDisposed 19 687exercise · 2026-03-20
    • Kulkarni SamarthDirector, Chief Executive Officer · Restricted Stock Units → Common SharesAcquired 81 875grant · 2026-03-20
    • Kulkarni SamarthDirector, Chief Executive Officer · Stock Option (Right to Buy) → Common SharesAcquired 114 249 @ $46,24grant · 2026-03-20

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Regulatory filings
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • CRISPR Therapeutics AG company facts · 2026-08-01
    • CRISPR Therapeutics AG 10-Q 2026-05-04 · 2026-08-01
    • CRISPR Therapeutics AG 10-K 2026-02-12 · 2026-08-01
    • CRISPR Therapeutics AG 10-Q 2025-11-10 · 2026-08-01
    • CRISPR Therapeutics AG 10-Q 2025-08-04 · 2026-08-01
    • allocator_boost (allocator) on CRSP · 2026-08-01
    • CRISPR Therapeutics AG Market data — analyst estimates · 2026-08-01
    • CRISPR Therapeutics AG Market data — ESG · 2026-08-01
    • CRISPR Therapeutics AG HA canonical relationships · 2026-08-01

    Ownership & reference

    Top holders

    • T. Rowe Price Investment Management, Inc.Investment Managers · as of 2026-03-310,10 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,01 %$84M
    • Capital Research Global InvestorsInvestment Managers · as of 2026-03-310,01 %$56M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,01 %$49M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,01 %$113M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,01 %$189M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,01 %$38M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$93M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$23M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$150M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$10M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$14M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$6M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$15M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$13M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$20M
    • EATON VANCE MANAGEMENTInstitutional Investor · as of 2022-09-300,00 %$0M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$7M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$32M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$119M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$5M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$3M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$2M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$3M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$2M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • Samarth KulkarniChairman of the Board, Chief Executive Officer

    Insider activity

    Net selling0 buys · 12 sellsnet -$3,3M4 insiders · last 365d
    • Patel NaimishChief Medical Officer · Common SharesSold 3 786 @ $55,62$211K · 2026-05-29
    • Patel NaimishChief Medical Officer · Common SharesOther 10 000 · 2026-05-28
    • Kulkarni SamarthDirector, Chief Executive Officer · Common SharesSold 10 020 @ $46,78$469K · 2026-03-23
    • KASINGER JAMES R.General Counsel and Secretary · Common SharesSold 3 182 @ $46,78$149K · 2026-03-23
    • Prasad RajuChief Financial Officer · Common SharesSold 3 708 @ $46,78$173K · 2026-03-23
    • Kulkarni SamarthDirector, Chief Executive Officer · Common SharesOther 19 687 · 2026-03-20
    • KASINGER JAMES R.General Counsel and Secretary · Common SharesOther 6 250 · 2026-03-20
    • Prasad RajuChief Financial Officer · Common SharesOther 6 250 · 2026-03-20
    • Prasad RajuChief Financial Officer · Common SharesSold 4 021 @ $48,26$194K · 2026-03-16
    • Patel NaimishChief Medical Officer · Common SharesSold 3 150 @ $48,26$152K · 2026-03-16
    • Prasad RajuChief Financial Officer · Common SharesSold 5 848 @ $48,26$282K · 2026-03-16
    • Prasad RajuChief Financial Officer · Common SharesOther 750 · 2026-03-16
    • KASINGER JAMES R.General Counsel and Secretary · Common SharesSold 3 450 @ $48,26$166K · 2026-03-16
    • Kulkarni SamarthDirector, Chief Executive Officer · Common SharesSold 10 349 @ $48,26$499K · 2026-03-16
    • Kulkarni SamarthDirector, Chief Executive Officer · Common SharesOther 20 625 · 2026-03-14
    • Prasad RajuChief Financial Officer · Common SharesOther 6 875 · 2026-03-14
    • Prasad RajuChief Financial Officer · Common SharesOther 10 000 · 2026-03-14
    • Patel NaimishChief Medical Officer · Common SharesOther 8 125 · 2026-03-14
    • KASINGER JAMES R.General Counsel and Secretary · Common SharesOther 6 875 · 2026-03-14
    • Kulkarni SamarthDirector, Chief Executive Officer · Common SharesSold 9 798 @ $52,80$517K · 2026-03-11
    • KASINGER JAMES R.General Counsel and Secretary · Common SharesSold 2 800 @ $52,80$148K · 2026-03-11
    • KASINGER JAMES R.General Counsel and Secretary · Common SharesOther 5 500 · 2026-03-10
    • Kulkarni SamarthDirector, Chief Executive Officer · Common SharesOther 19 250 · 2026-03-10
    • Kulkarni SamarthDirector, Chief Executive Officer · Common SharesSold 6 967 @ $52,58$366K · 2026-02-19
    • Kulkarni SamarthDirector, Chief Executive Officer · Common SharesOther 13 250 · 2026-02-18

    Short positioning

    19.8Mshares short-2.9% vs prior
    11.56days to cover
    46.2%short of daily vol
    467.7Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    CRSPCanonical
    Nasdaq · USD

    Intel & risk

    PredictorBeat prob44 %Surprise-0,05M&A prob3 %Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskMedium
    Liquidity riskLow
    Source documents mention dilution or offering risk.
    Relationship graph
    CRSPLLY.NVRTX.OEX21:003EX21:1d4EX21:a7fEX21:b7bBiotechnology
    This companySectorPartnersSubsidiaries

    Evidence & claims

    From filings & derived data
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): -8.2%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): -90.6%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -0.5%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 10.8%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 1.0%Derived (calculated)
    • Net margin (FY 2025-12-31): -16,569.8%Derived (calculated)
    • Return on equity (FY 2025-12-31): -30.3%Derived (calculated)
    • Return on assets (FY 2025-12-31): -25.7%Derived (calculated)
    • Current ratio (FY 2025-12-31): 13.32xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.18xDerived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): -51.9%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 16.5%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -49.1%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -49.1%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -58.8%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -141.7%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -42.4%Derived (calculated)
    • Current assets (annual): USD 1.99BSEC XBRL filing
    • Total assets (annual): USD 2.27BSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -6SEC XBRL filing
    • Current liabilities (annual): USD 149.12MSEC XBRL filing
    • Pre-tax income (annual): USD -577.97MSEC XBRL filing
    • R&D expense (annual): USD 284.81MSEC XBRL filing
    • Operating income (annual): USD -664.57MSEC XBRL filing
    Showing 24 of 57 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-08-03 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
    2026-08-03EVENTQ2 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-25 03:10 UTCHOLDERInstitutional holding changed
    2026-06-25 03:10 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-05 00:00 UTCINSIDER10 insider transactions — 2026-06 10 derivative
    2026-06-05INSIDERGeorge Simeon acquired 13.0k sh Stock Option (Right to Buy) — Director
    2026-06-05INSIDERMahatme Sandesh acquired 13.0k sh Stock Option (Right to Buy) — Director
    2026-06-05INSIDERMorrison Briggs acquired 13.0k sh Stock Option (Right to Buy) — Director
    2026-06-05INSIDERRommel Christian acquired 13.0k sh Stock Option (Right to Buy) — Director
    2026-06-05INSIDERTreco Douglas A acquired 13.0k sh Stock Option (Right to Buy) — Director
    2026-06-05INSIDERBehbahani Ali acquired 13.0k sh Stock Option (Right to Buy) — Director
    2026-06-05INSIDERFardis Maria acquired 13.0k sh Stock Option (Right to Buy) — Director
    2026-06-05INSIDERFleming Harold Edward acquired 13.0k sh Stock Option (Right to Buy) — Director
    2026-06-05INSIDERGreene John acquired 13.0k sh Stock Option (Right to Buy) — Director
    2026-06-05INSIDERHigh Katherine A acquired 13.0k sh Stock Option (Right to Buy) — Director
    2026-06-04FILING8-K filing →
    2026-05-29 00:00 UTCINSIDER6 insider transactions — 2026-05 · net sell $211k 4 derivative
    2026-05-29INSIDERPatel Naimish sold 3.8k sh Common Shares — Chief Medical Officer ~$211k
    2026-05-29INSIDERKASINGER JAMES R. acquired 17.0k sh Restricted Stock Units — General Counsel and Secretary
    2026-05-29INSIDERPatel Naimish acquired 22.0k sh Restricted Stock Units — Chief Medical Officer
    2026-05-29INSIDERPrasad Raju acquired 19.5k sh Restricted Stock Units — Chief Financial Officer
    2026-05-28INSIDERPatel Naimish transacted 10.0k sh Common Shares — Chief Medical Officer
    2026-05-28INSIDERPatel Naimish disposed of 10.0k sh Restricted Stock Units — Chief Medical Officer
    2026-05-04FILING10-Q filing →
    2026-05-04FILING8-K filing →
    2026-04-21FILINGDEF 14A filing →
    2026-03-31EARNINGSQuarterly results — Q4 2025 Revenue USD 1.5M · Net USD -122.9M
    2026-03-23 00:00 UTCINSIDER39 insider transactions — 2026-03 · net sell $2.8M 18 derivative
    2026-03-23INSIDERKulkarni Samarth sold 10.0k sh Common Shares — Director, Chief Executive Officer ~$469k
    2026-03-23INSIDERKASINGER JAMES R. sold 3.2k sh Common Shares — General Counsel and Secretary ~$149k
    2026-03-23INSIDERPrasad Raju sold 3.7k sh Common Shares — Chief Financial Officer ~$173k
    2026-03-20INSIDERKulkarni Samarth transacted 19.7k sh Common Shares — Director, Chief Executive Officer
    Showing the 40 most recent of 75 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage